CONTROL OF DRUG AND ETHANOL METABOLISM

药物和乙醇代谢的控制

基本信息

  • 批准号:
    3108855
  • 负责人:
  • 金额:
    $ 19.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1978
  • 资助国家:
    美国
  • 起止时间:
    1978-03-01 至 1994-07-31
  • 项目状态:
    已结题

项目摘要

The three specific aims of this project arise from a long-standing interest of the applicant in the effects of ethanol on hepatic oxygen metabolism. The long-range goals of this project are to determine mechanic of hepatotoxicity and ultimately to develop methods to prevent liver damage in human alcoholics, a pathology that originates in pericentral regions of the liver lobule. We have found that the natural distribution of oxygen across the liver lobule regulates metabolic compartmentation of key hepatic biochemical processes; therefore, we plan to systematically evaluate the hypothesis that oxygen regulates oxygen uptake via a physiological negative feedback system by producing unique second messenger molecules which alter intracellular calcium in the liver. Specifically, this goal will be achieved by studying the effect of O2 on intracellular free Ca++ and respiration of fresh plugs of tissue isolated from periportal and pericentral regions of the liver lobule. Next, we plan to identify the effect of oxygen tension on the production of eicosanoids and inositol phosphate second messengers involved in the process. Moreover, we plan to identify the effects of products of enzymes with high Km's for oxygen on intracellular free calcium and we will elucidate the mechanism of action of intracellular calcium on mitochondria isolated from periportal and pericentral regions of the liver lobule. In these experiments, we will couple specific microprobe detector systems developed in this laboratory to oxygen uptake and other important hepatic metabolic events in periportal and pericentral regions of the liver lobule in perfused livers from normal and ethanol-treated rats. We demonstrated recently that catalase-H2O2 can participate significantly in hepatic ethanol metabolism in perfused rat and deermouse livers if provided with adequate substrate in the form of albumin-bound fatty acids. Since ethanol causes lipid to accumulate in the liver, we plan to evaluate the hypothesis that ethanol activates the catalase pathway of ethanol metabolism by providing fatty acids for H2O2 generation by comparing rates of alcohol oxidation by perfused livers, from ADH~ deermice with peroxisomal beta-oxidation in vitro, by evaluating the above pathway in diurnal variation in ethanol metabolism in ADH~ deermice in vivo, and by studying the effect of acute and chronic treatment with ethanol on this important but previously overlooked pathway. We also recently discovered that fatty acid-albumin complexes can produce toxic O2 species (e.g., H2O2) at high rates in the perfused liver. Since fat accumulates initially in pericentral regions of the liver lobule where peroxisomes predominate, we plan to evaluate the hypothesis that ethanol-induced hepatotoxicity is due to local production of reduced oxygen species in cells localized around the central vein. First, models will be developed to study alcohol- induced liver damage in the ADH~ deermouse. Next, methods will be developed to study the accumulation of lipid and the production of hydrogen of hydrogen peroxide dynamically in periportal and pericentral regions of the liver lobule based on the fluorescent properties of lipophilic dyes and the absorption characteristics of the H2O2-complex using perfused rat and deermouse livers respectively. Finally, reduced oxygen species and lipid radicals will be trapped and determined by electron spin resonance in livers from ethanol treated rats and deermice. Once we understand the role of hepatic lipid and oxygen tension in chromic alcoholic liver disease, we can provide the first critical step in rational therapy for this widespread disease.
这个项目的三个具体目标源于一个长期的

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RONALD G THURMAN其他文献

RONALD G THURMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RONALD G THURMAN', 18)}}的其他基金

GENE THERAPY FOR ALCOHOLIC LIVER DISEASE
酒精性肝病的基因治疗
  • 批准号:
    6563211
  • 财政年份:
    2001
  • 资助金额:
    $ 19.97万
  • 项目类别:
GENE THERAPY FOR ALCOHOLIC LIVER DISEASE
酒精性肝病的基因治疗
  • 批准号:
    6410007
  • 财政年份:
    2000
  • 资助金额:
    $ 19.97万
  • 项目类别:
PREVENTION OF ARTHRITIS WITH DIETARY GLYCINE
用膳食甘氨酸预防关节炎
  • 批准号:
    6338638
  • 财政年份:
    2000
  • 资助金额:
    $ 19.97万
  • 项目类别:
PREVENTION OF ARTHRITIS WITH DIETARY GLYCINE
用膳食甘氨酸预防关节炎
  • 批准号:
    6201494
  • 财政年份:
    1999
  • 资助金额:
    $ 19.97万
  • 项目类别:
GENE THERAPY FOR ALCOHOLIC LIVER DISEASE
酒精性肝病的基因治疗
  • 批准号:
    6200918
  • 财政年份:
    1999
  • 资助金额:
    $ 19.97万
  • 项目类别:
GENE THERAPY AND ALCOHOL-INDUCED FIBROSIS
基因治疗和酒精引起的纤维化
  • 批准号:
    6074637
  • 财政年份:
    1999
  • 资助金额:
    $ 19.97万
  • 项目类别:
GENE TECHNOLOGY THERAPY AND ALCOHOL-INDUCED FIBROSIS
基因技术治疗和酒精引起的纤维化
  • 批准号:
    6168539
  • 财政年份:
    1999
  • 资助金额:
    $ 19.97万
  • 项目类别:
GENE THERAPY FOR ALCOHOLIC LIVER DISEASE
酒精性肝病的基因治疗
  • 批准号:
    6097738
  • 财政年份:
    1998
  • 资助金额:
    $ 19.97万
  • 项目类别:
PREVENTION OF ARTHRITIS WITH DIETARY GLYCINE
用膳食甘氨酸预防关节炎
  • 批准号:
    6100400
  • 财政年份:
    1998
  • 资助金额:
    $ 19.97万
  • 项目类别:
GENE THERAPY FOR ALCOHOLIC LIVER DISEASE
酒精性肝病的基因治疗
  • 批准号:
    6267147
  • 财政年份:
    1997
  • 资助金额:
    $ 19.97万
  • 项目类别:

相似海外基金

Acyl-CoA合成酵素ACSL3のオートファジーにおける役割の解明
阐明酰基辅酶 A 合成酶 ACSL3 在自噬中的作用
  • 批准号:
    24KJ2017
  • 财政年份:
    2024
  • 资助金额:
    $ 19.97万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Ceramides as Novel Mediators of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency-Induced Heart Failure.
神经酰胺作为极长链酰基辅酶A脱氢酶缺乏引起的心力衰竭的新型介体。
  • 批准号:
    10747561
  • 财政年份:
    2023
  • 资助金额:
    $ 19.97万
  • 项目类别:
Acyl-CoA synthetase-mediated regulation of lipid homeostasis
酰基辅酶A合成酶介导的脂质稳态调节
  • 批准号:
    10189414
  • 财政年份:
    2021
  • 资助金额:
    $ 19.97万
  • 项目类别:
Regulation of acyl-CoA-related enzymes by enzymatically inactive enzyme homolog
酶无活性酶同系物对酰基辅酶A相关酶的调节
  • 批准号:
    20K05804
  • 财政年份:
    2020
  • 资助金额:
    $ 19.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Estimation for severity and treatment efficacy of very-long-chain acyl-CoA dehydrogenase deficiency via fatty acid loading test
通过脂肪酸负荷试验评估极长链酰基辅酶A脱氢酶缺乏症的严重程度和治疗效果
  • 批准号:
    19K17355
  • 财政年份:
    2019
  • 资助金额:
    $ 19.97万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Characterization of the sex specific metabolic phenotype in very-long chain acyl-CoA dehydrogenase deficient (VLCAD-/-) mice
极长链酰基辅酶 A 脱氢酶缺陷 (VLCAD-/-) 小鼠性别特异性代谢表型的表征
  • 批准号:
    410964249
  • 财政年份:
    2018
  • 资助金额:
    $ 19.97万
  • 项目类别:
    Research Grants
Transport mechanism of very long chain fatty acyl-CoA into peroxisomes mediated by peroxisomal ABC protein ABCD1
过氧化物酶体ABC蛋白ABCD1介导的极长链脂肪酰辅酶A转运至过氧化物酶体的机制
  • 批准号:
    18K14900
  • 财政年份:
    2018
  • 资助金额:
    $ 19.97万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Involvement of acyl-CoA thioester metabolite in drug-induced idiosyncratic liver injury
酰基辅酶A硫酯代谢物参与药物引起的特异质肝损伤
  • 批准号:
    17K08432
  • 财政年份:
    2017
  • 资助金额:
    $ 19.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Branched chain acyl-CoA metabolism and disease
支链酰基辅酶A代谢与疾病
  • 批准号:
    9308948
  • 财政年份:
    2016
  • 资助金额:
    $ 19.97万
  • 项目类别:
Branched chain acyl-CoA metabolism and disease
支链酰基辅酶A代谢与疾病
  • 批准号:
    9130361
  • 财政年份:
    2016
  • 资助金额:
    $ 19.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了